226 related articles for article (PubMed ID: 36424024)
21. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
22. Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S; Klotz U
Eur J Clin Pharmacol; 2008 Mar; 64(3):233-52. PubMed ID: 17999057
[TBL] [Abstract][Full Text] [Related]
23. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Pelletier JP; Martel-Pelletier J; Rannou F; Cooper C
Semin Arthritis Rheum; 2016 Feb; 45(4 Suppl):S22-7. PubMed ID: 26806184
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P; Henry D
JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
[TBL] [Abstract][Full Text] [Related]
26. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups.
Solomon DH; Glynn RJ; Rothman KJ; Schneeweiss S; Setoguchi S; Mogun H; Avorn J; Stürmer T
Arthritis Rheum; 2008 Aug; 59(8):1097-104. PubMed ID: 18668605
[TBL] [Abstract][Full Text] [Related]
27. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
Maillard M; Burnier M
Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958
[TBL] [Abstract][Full Text] [Related]
28. The murky waters of the coxibs: a review of the current state of play.
Ostor AJ; Hazleman BL
Inflammopharmacology; 2005; 13(4):371-80. PubMed ID: 16354390
[TBL] [Abstract][Full Text] [Related]
29. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
Moore RA; Derry S; McQuay HJ
BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Konstam MA; Weir MR; Reicin A; Shapiro D; Sperling RS; Barr E; Gertz BJ
Circulation; 2001 Nov; 104(19):2280-8. PubMed ID: 11696466
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
32. Review of the cardiovascular safety of COXIBs compared to NSAIDS.
Moodley I
Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356
[TBL] [Abstract][Full Text] [Related]
33. Gastrointestinal and cardiovascular adverse events associated with NSAIDs.
Domper Arnal MJ; Hijos-Mallada G; Lanas A
Expert Opin Drug Saf; 2022 Mar; 21(3):373-384. PubMed ID: 34376069
[TBL] [Abstract][Full Text] [Related]
34. Non-steroidal anti-inflammatory drugs for acute gout.
van Durme CM; Wechalekar MD; Buchbinder R; Schlesinger N; van der Heijde D; Landewé RB
Cochrane Database Syst Rev; 2014 Sep; (9):CD010120. PubMed ID: 25225849
[TBL] [Abstract][Full Text] [Related]
35. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
36. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
Joshi GP; Gertler R; Fricker R
Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
[TBL] [Abstract][Full Text] [Related]
38. Anti-inflammatory drugs in the 21st century.
Rainsford KD
Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
[TBL] [Abstract][Full Text] [Related]
39. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
[TBL] [Abstract][Full Text] [Related]
40. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
Bruno A; Tacconelli S; Patrignani P
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
